AMGEN Inc.

NASDAQ:AMGN  
209.27
+0.28 (+0.13%)
4:00:00 PM EDT: $209.24 -0.03 (-0.01%)
Products

Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With Kras G12c Mutation

Published: 12/16/2020 21:45 GMT
AMGEN Inc. (AMGN) - Amgen Submits Sotorasib New Drug Application to U.S. FDA for Advanced Or Metastatic Non-small Cell Lung Cancer With Kras G12c Mutation.
Amgen Inc - FDA Granted Breakthrough Therapy Designation for Sotorasib.
Amgen Inc - Sotorasib Application Being Reviewed Under FDA Real-time Oncology Review (rtor) Pilot Program.